Urooba Nadeem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Urooba Nadeem has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ang Gao
O’Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA
20 shared publications - Arjun Gupta
City of Hope Cancer Center, Phoenix, AZ
20 shared publications - David E. Gerber
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX
20 shared publications - David Ross Camidge
University of Colorado Cancer Center, Aurora, CO 80045, USA
20 shared publications - Farjana Fattah
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
20 shared publications - Hong Mu-Mosley
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
20 shared publications
Latest Publications
- Open Access
Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut–Lung-Immune Axis
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains the leading cause of cancer mortality worldwide. While immune checkpoint inhibitors (ICIs) have revolutionized treatment, primary and acquired resistance, and immune-related adverse events (irAEs) limit their therapeutic efficacy. Recent evidence highlights the gut and local microbial communities as a modifiable determinant of NSCLC outcomes, especially in the context of ICI use. Emerging data support the concept of a gut–lung-immune axis, a tridirectional communication pathway, in which gut and lung microbial communities influence local and systemic antitumor immunity through immune cell trafficking, cytokine signaling, and microbial-derived metabolites. In this review, we synthesize current clinical and mechanistic studies examining the role of gut, tumor-resident, and circulating microbiota in shaping ICI efficacy and toxicity in NSCLC. Distinct gut and tumor microbial signatures, such as the abundance of Akkermansia muciniphila and Bifidobacterium, correlate with improved ICI response, whereas dysbiosis promotes immune suppression, resistance, and irAEs. Additionally, we highlight emerging microbial-based biomarkers, including fecal microbial profiles, circulating microbial DNA, and composite tools such as TOPOSCORE, which show promise for predicting response, toxicity, and optimal treatment duration. Overall, these findings underscore the gut–lung-immune axis as a key regulator of immunotherapy outcomes in NSCLC and suggest that microbiome-informed strategies may enable more precise, effective, and safer personalization of ICI therapy.
Open AccessMicrobial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut–Lung-Immune Axis
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains the leading cause of cancer mortality worldwide. While immune checkpoint inhibitors (ICIs) have revolutionized treatment, primary and acquired resistance, and immune-related adverse events (irAEs) limit their therapeutic efficacy. Recent evidence highlights the gut and local microbial communities as a modifiable determinant of NSCLC outcomes, especially in the context of ICI use. Emerging data support the concept of a gut–lung-immune axis, a tridirectional communication pathway, in which gut and lung microbial communities influence local and systemic antitumor immunity through immune cell trafficking, cytokine signaling, and microbial-derived metabolites. In this review, we synthesize current clinical and mechanistic studies examining the role of gut, tumor-resident, and circulating microbiota in shaping ICI efficacy and toxicity in NSCLC. Distinct gut and tumor microbial signatures, such as the abundance of Akkermansia muciniphila and Bifidobacterium, correlate with improved ICI response, whereas dysbiosis promotes immune suppression, resistance, and irAEs. Additionally, we highlight emerging microbial-based biomarkers, including fecal microbial profiles, circulating microbial DNA, and composite tools such as TOPOSCORE, which show promise for predicting response, toxicity, and optimal treatment duration. Overall, these findings underscore the gut–lung-immune axis as a key regulator of immunotherapy outcomes in NSCLC and suggest that microbiome-informed strategies may enable more precise, effective, and safer personalization of ICI therapy.
- 18 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (20) , 1447-1452
Twin Diseases in Different Organs: A Cautionary Tale of Anchoring on a Positive Scan
- 18 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (20) , 1447-1452
Twin Diseases in Different Organs: A Cautionary Tale of Anchoring on a Positive Scan
- 23 February 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (6) , 1383-1392
Primary Renal Well-Differentiated Neuroendocrine Tumor: A Clinicopathologic and Immunohistochemical Analysis of a Case Series With Emphasis on Potential Diagnostic Pitfalls
Introduction . Primary renal well-differentiated neuroendocrine tumor may present a unique diagnostic and therapeutic challenge. In this retrospective study, we offered insights derived from our clinical experience. Methods . A search of our institutional database (1998–2023) was performed to identify primary renal well-differentiated neuroendocrine tumors, followed by comprehensive clinical, histopathological and immunohistochemical analysis, with emphasis on potential diagnostic pitfalls. Results . Five primary renal well-differentiated neuroendocrine tumors were identified, all of which exhibited a combination of nested, trabecular and tubular growth patterns and renal parenchymal infiltration. Two tumors invaded into the renal sinus. The expression of commonly-used neuroendocrine markers was detected in 5 tumors and PAX8 immunostain was negative in all tumors. During a median follow-up of 119 months (range 12–142 months), one patient received adjuvant chemotherapy due to regional lymph node metastasis at the time of diagnosis. The patient was found to haveliver metastasis at 15 months after the surgery by imaging. This tumor harbored BRAF c.1/99T>A, p.V600E and CDKN2A c.35delC, p.S12fs variants. Liver metastasis was identified in another patient 142 months after his initial presentation. No local recurrence or distant metastasis was detected in other patients. Conclustions . Our experience demonstrates that primary renal well-differentiated neuroendocrine tumors may exhibit indolent behavior, even tumors with local invasion. Most patients were managed with surgical resection alone. In daily practice, they may be misdiagnosed as renal cell carcinomas, especially in biopsy specimens, due to their rarity. Our study expands the clinicopathologic characteristics and immunohistochemical features of this rare entity to raise awareness, with emphasis on potential diagnostic pitfalls.
- 23 February 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (6) , 1383-1392
Primary Renal Well-Differentiated Neuroendocrine Tumor: A Clinicopathologic and Immunohistochemical Analysis of a Case Series With Emphasis on Potential Diagnostic Pitfalls
Introduction . Primary renal well-differentiated neuroendocrine tumor may present a unique diagnostic and therapeutic challenge. In this retrospective study, we offered insights derived from our clinical experience. Methods . A search of our institutional database (1998–2023) was performed to identify primary renal well-differentiated neuroendocrine tumors, followed by comprehensive clinical, histopathological and immunohistochemical analysis, with emphasis on potential diagnostic pitfalls. Results . Five primary renal well-differentiated neuroendocrine tumors were identified, all of which exhibited a combination of nested, trabecular and tubular growth patterns and renal parenchymal infiltration. Two tumors invaded into the renal sinus. The expression of commonly-used neuroendocrine markers was detected in 5 tumors and PAX8 immunostain was negative in all tumors. During a median follow-up of 119 months (range 12–142 months), one patient received adjuvant chemotherapy due to regional lymph node metastasis at the time of diagnosis. The patient was found to haveliver metastasis at 15 months after the surgery by imaging. This tumor harbored BRAF c.1/99T>A, p.V600E and CDKN2A c.35delC, p.S12fs variants. Liver metastasis was identified in another patient 142 months after his initial presentation. No local recurrence or distant metastasis was detected in other patients. Conclustions . Our experience demonstrates that primary renal well-differentiated neuroendocrine tumors may exhibit indolent behavior, even tumors with local invasion. Most patients were managed with surgical resection alone. In daily practice, they may be misdiagnosed as renal cell carcinomas, especially in biopsy specimens, due to their rarity. Our study expands the clinicopathologic characteristics and immunohistochemical features of this rare entity to raise awareness, with emphasis on potential diagnostic pitfalls.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 4. Cytokine changes (post-selinexor, pre-docetaxel) significantly associated with clinical outcomes.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 4. Cytokine changes (post-selinexor, pre-docetaxel) significantly associated with clinical outcomes.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 1. Next generation sequencing results (n=16 cases).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 1. Next generation sequencing results (n=16 cases).
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 3. Baseline cytokines significantly associated with clinical outcomes.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 3. Baseline cytokines significantly associated with clinical outcomes.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 5. Sample radiographic responses (n=3, all TP53 wild type).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 5. Sample radiographic responses (n=3, all TP53 wild type).
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Table 1. Representativeness of study participants.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Table 1. Representativeness of study participants.